Search Results - "Lovly, C M"

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors by Westover, D, Zugazagoitia, J, Cho, B C, Lovly, C M, Paz-Ares, L

“…Abstract Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating mutations within the epidermal growth factor receptor (EGFR)…”
Get full text

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer by Schoenfeld, A.J., Antonia, S.J., Awad, M.M., Felip, E., Gainor, J., Gettinger, S.N., Hodi, F.S., Johnson, M.L., Leighl, N.B., Lovly, C.M., Mok, T., Perol, M., Reck, M., Solomon, B., Soria, J.-C., Tan, D.S.W., Peters, S., Hellmann, M.D.

“…Acquired resistance (AR) to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] blockade is frequent in non-small-cell lung cancer (NSCLC),…”
Get full text

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas by Selenica, P., Marra, A., Choudhury, N.J., Gazzo, A., Falcon, C.J., Patel, J., Pei, X., Zhu, Y., Ng, C.K.Y., Curry, M., Heller, G., Zhang, Y.-K., Berger, M.F., Ladanyi, M., Rudin, C.M., Chandarlapaty, S., Lovly, C.M., Reis-Filho, J.S., Yu, H.A.

“…Studies of targeted therapy resistance in lung cancer have primarily focused on single-gene alterations. Based on prior work implicating apolipoprotein b…”
Get full text

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib by Oztan, A., Fischer, S., Schrock, A.B., Erlich, R.L., Lovly, C.M., Stephens, P.J., Ross, J.S., Miller, V., Ali, S.M., Ou, S.-H.I., Raez, L.E.

“…•Resistance to the T790M-specific inhibitor, osimertinib, is incompletely defined.•EGFR G724S mutation was found in two NSCLC cases post-progression on…”
Get full text

Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) by Horn, L., Whisenant, J.G., Wakelee, H., Reckamp, K.L., Qiao, H., Du, L., Hernandez, J., Huang, V., Waqar, S.N., Patel, S., Sanborn, R.E., Shaffer, T., Garg, K., Holzhausen, A., Harrow, K., Liang, C., Lim, L.P., Li, M., Lovly, C.M.

Get full text

Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding by GRAVES, Paul R, LOVLY, Christine M, UY, Geoffrey L, PIWNICA-WORMS, Helen

“…Entry into mitosis requires activation of the Cdc2 protein kinase by the Cdc25C protein phosphatase. The interactions between Cdc2 and Cdc25C are negatively…”
Get full text

112OCirculating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) by Horn, L, Whisenant, J G, Wakelee, H, Reckamp, K L, Qiao, H, Du, L, Hernandez, J, Huang, V, Waqar, S N, Patel, S, Sanborn, R E, Shaffer, T, Garg, K, Holzhausen, A, Harrow, K, Liang, C, Lim, L P, Li, M, Lovly, C M

Get full text

DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment—A catalogue of clinically relevant somatic mutations in lung cancer by Horn, L., Chen, H., Lovly, C. M., Andrews, J., Yeh, P., Levy, M. A., Pao, W.

“…Abstract only…”
Get full text

Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors by Lovly, C. M., de Stanchina, E., Chen, H., Liang, C., Pao, W.

“…Abstract only…”
Get full text

My Cancer Genome: Web-based clinical decision support for genome-directed lung cancer treatment by Levy, M. A., Lovly, C. M., Horn, L., Naser, R., Pao, W.

“…Abstract only…”
Get full text

Abstract P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer by Hanker, AB, Red Brewer, M, Sheehan, JH, Koch, JP, Lanman, R, Hyman, DM, Cutler, RE, Lalani, AS, Cross, D, Lovly, CM, Meiler, J, Arteaga, CL

“…ERBB2, the gene encoding HER2, is mutated in 2-4% of breast cancers. The HER2 irreversible tyrosine kinase inhibitor (TKI) neratinib has shown clinical…”
Get full text

Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation by SCHWARZ, Julie K, LOVLY, Christine M, PIWNICA-WORMS, Helen

“…Chk2 is a serine/threonine protein kinase found mutated in certain hereditary and sporadic cancers. Ionizing radiation (IR) activates the kinase activity of…”
Get full text

Accurate Mass-Driven Analysis for the Characterization of Protein Phosphorylation. Study of the Human Chk2 Protein Kinase by King, Julie B, Gross, Julia, Lovly, Christine M, Rohrs, Henry, Piwnica-Worms, Helen, Townsend, R. Reid

“…We describe the data-dependent analysis of protein phosphorylation using rapid-acquisition nano-LC−linear quadrupole ion trap Fourier transform ion cyclotron…”
Get full text